A systematic review and economic model of the effectiveness and ...

18 TABLE 2
Clinical effectiveness
An overview of trials included in the review – and comparators (cont’d)
Study
Placebo/st. comm. care/attent. contr.
Non-drug (+ placebo)
MPH low dose
MPH medium dose
MPH high dose
MPH low dose + non-drug
MPH medium dose + non-drug
MPH high dose + non-drug
MPH-SR low dose
MPH-SR medium dose
MPH-SR high dose
MPH-SR low dose + non-drug
MPH-SR medium dose + non-drug
MPH-SR high dose + non-drug
MPH low dose + MPH-SR 20 mg
MPH + thioridazine hydrochloride
DEX low dose
DEX medium dose
DEX high dose
DEX medium dose + non-drug
DEX high dose + non-drug
DEX-TR/ER
DEX-SR + non-drug
ATX L+M
ATX H
Caffeine
Pemoline
Pemoline + non-drug
Imipramine
Adderall
Adderall + non-drug
MAOI + diet
GLA 500 mg + vitamin E
Chlorpromazine
Hydroxyzine
Levoamphetamine
Thioridazine hydrochloride
Pindolol
Age (years) IQ
4.0–5.1 60 × × ×
6.1–18.2 NR × × ×
6.9–12.2 100 × × × ×
6.0–12 NR × ×
[Confidential information removed]
6.0–12 NR × × ×
12.0–19 101 × ×
12.0–18 109 × ×
5.6–11.9 109 × ×
7.0–13 NR × × × × × ×
7.0–15 NR × ×
7.0–13 94 × 2 ×
5.0–17 NR × × 2
8.0–18 NR × 2 ×
6.0–16 NR × ×
6.0–15 NR × ×
7–9.9 101 × × × ×
6.5–11 95 × × ×
8.1–13.2 106 × × × × ×
5.4–9.9 111 × × × × × ×
5.8–12.7 NR × × × 2
6.0–12 110 × × 2 3
6.0–12 105 × × ×
6.0–11 NR × × ×
Handen, 199960 Hoeppner, 1997 61
James, 2001 62
Kelsey, 2004 63
Kemner, 2004 99
Klein, 1997 65
Klorman, 1987 66
Klorman, 1990 67
Klorman, 1994 68
Kolko, 1999 69
Kratochvil, 2002 70
Kupietz, 1988 71
Manos, 1999 72
Michelson, 2001 73
Michelson, 2002 74
Michelson, 2004 75
MTA, 1999 76
Pelham, 1987 77
Pelham, 1990 78
Pelham, 1993 79
Pelham, 1999 80
Pelham, 1999 81
Pelham, 2001 82
Pliszka, 2000 100
continued